Pre-operative Overall Survival Time Prediction for Glioblastoma Patients Using Deep Learning on Both Imaging Phenotype and Genotype

Glioblastoma (GBM) is the most common and deadly malignant brain tumor with short yet varied overall survival (OS) time. Per request of personalized treatment, accurate pre-operative prognosis for GBM patients is highly desired. Currently, many machine learning-based studies have been conducted to predict OS time based on pre-operative multimodal MR images of brain tumor patients. However, tumor genotype, such as MGMT and IDH, which has been proven to have strong relationship with OS, is completely not considered in pre-operative prognosis as the genotype information is unavailable until craniotomy. In this paper, we propose a new deep learning based method for OS time prediction. It can derive genotype related features from pre-operative multimodal MR images of brain tumor patients to guide OS time prediction. Particularly, we propose a multi-task convolutional neural network (CNN) to accomplish tumor genotype and OS time prediction tasks. As the network can benefit from learning genotype related features toward genotype prediction, we verify upon a dataset of 120 GBM patients and conclude that the multi-task learning can effectively improve the accuracy of predicting OS time in personalized prognosis.

[1]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[2]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[3]  R. Jain,et al.  Deep learning for prediction of survival in idh wild-type gliomas , 2017, Journal of the Neurological Sciences.

[4]  Isabelle Camby,et al.  Present and potential future issues in glioblastoma treatment , 2006, Expert review of anticancer therapy.

[5]  Jieping Ye,et al.  Large-scale sparse logistic regression , 2009, KDD.

[6]  Peter Chang,et al.  Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. , 2018, AJR. American journal of roentgenology.

[7]  Dinggang Shen,et al.  3D Deep Learning for Multi-modal Imaging-Guided Survival Time Prediction of Brain Tumor Patients , 2016, MICCAI.

[8]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[9]  Bozena Kaminska,et al.  Clinical and immunological correlates of long term survival in glioblastoma , 2018, Contemporary oncology.

[10]  Chul-Kee Park,et al.  The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas , 2017, Acta Neuropathologica Communications.

[11]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[12]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[13]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[14]  R. Colen,et al.  Imaging Genomics in Glioblastoma Multiforme: A Predictive Tool for Patients Prognosis, Survival, and Outcome. , 2016, Magnetic resonance imaging clinics of North America.

[15]  Daniel J Brat,et al.  Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.

[16]  R. F. Woolson Wilcoxon Signed-Rank Test , 2008 .